BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36579994)

  • 1. Possible Use of miR-223-3p as a Prognostic Marker in Transarterial Chemoembolization Treatment of Hepatocellular Carcinoma Patients.
    E Abdelaziz H; El-Guendy N; Radwan EM; Sharawi SK; El-Houseini ME; Abdel-Wahab AA
    Asian Pac J Cancer Prev; 2022 Dec; 23(12):4125-4135. PubMed ID: 36579994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-372-3p Predicts Response of TACE Patients Treated with Doxorubicin and Enhances Chemosensitivity in Hepatocellular Carcinoma.
    Soliman MH; Ragheb MA; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
    Anticancer Agents Med Chem; 2021; 21(2):246-253. PubMed ID: 32416702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-520c-3p Modulates Doxorubicin-Chemosensitivity in HepG2 Cells.
    Ragheb MA; Soliman MH; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
    Anticancer Agents Med Chem; 2021; 21(2):237-245. PubMed ID: 32357822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA H19 modulated by miR-146b-3p/miR-1539-mediated allelic regulation in transarterial chemoembolization of hepatocellular carcinoma.
    Song Y; Xing H; Zhou L; Zhang N; Yang M
    Arch Toxicol; 2021 Sep; 95(9):3063-3070. PubMed ID: 34251499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
    Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
    World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of the miR-325-3p/DPAGT1 axis supports HBV-positive HCC chemoresistance.
    Li R; Xu T; Wang H; Wu N; Liu F; Jia X; Mi J; Lv J; Gao H
    Biochem Biophys Res Commun; 2019 Nov; 519(2):358-365. PubMed ID: 31519321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma.
    Kim SS; Nam JS; Cho HJ; Won JH; Kim JW; Ji JH; Yang MJ; Park JH; Noh CK; Shin SJ; Lee KM; Cho SW; Cheong JY
    J Gastroenterol Hepatol; 2017 Jan; 32(1):199-207. PubMed ID: 27194671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival.
    Liu M; Liu J; Wang L; Wu H; Zhou C; Zhu H; Xu N; Xie Y
    PLoS One; 2014; 9(10):e109347. PubMed ID: 25275448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
    Kim SS; Cho HJ; Nam JS; Kim HJ; Kang DR; Won JH; Kim J; Kim JK; Lee JH; Kim BH; Lee MY; Cho SW; Cheong JY
    J Korean Med Sci; 2018 Jan; 33(1):e6. PubMed ID: 29215815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
    J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization.
    Ali HEA; Emam AA; Zeeneldin AA; Srour R; Tabashy R; El-Desouky ED; Abd Elmageed ZY; Abdel-Wahab AA
    Clin Biochem; 2019 Mar; 65():45-52. PubMed ID: 30653948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies.
    Sun Z; Zhao Z; Li G; Dong S; Huang Z; Ye L; Liang H; Qu J; Ai X; Zhang W; Chen X
    Tumori; 2010; 96(1):90-6. PubMed ID: 20437864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-1285-3p acts as a potential tumor suppressor miRNA via downregulating JUN expression in hepatocellular carcinoma.
    Liu J; Yan J; Zhou C; Ma Q; Jin Q; Yang Z
    Tumour Biol; 2015 Jan; 36(1):219-25. PubMed ID: 25230788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.
    Nicolini D; Svegliati-Baroni G; Candelari R; Mincarelli C; Mandolesi A; Bearzi I; Mocchegiani F; Vecchi A; Montalti R; Benedetti A; Risaliti A; Vivarelli M
    World J Gastroenterol; 2013 Sep; 19(34):5622-32. PubMed ID: 24039354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
    Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
    Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma.
    Wei X; Zhao L; Ren R; Ji F; Xue S; Zhang J; Liu Z; Ma Z; Wang XW; Wong L; Liu N; Shi J; Guo X; Roessler S; Zheng X; Ji J
    Hepatology; 2021 Apr; 73(4):1381-1398. PubMed ID: 32609900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the pretreatment miRNA expression patterns of advanced hepatocellular carcinoma patients in association with response to TACE treatment.
    El-Halawany MS; Ismail HM; Zeeneldin AA; Elfiky A; Tantawy M; Kobaisi MH; Hamed I; Abdel Wahab AH
    Biomed Res Int; 2015; 2015():649750. PubMed ID: 25811030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.